TY - T1的有意义的生存利益罪gle lung transplantation in idiopathic pulmonary fibrosis patients over 65 years of age JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02413-2019 VL - 56 IS - 1 SP - 1902413 AU - Peter Riddell AU - Jana Kleinerova AU - Donna Eaton AU - David G. Healy AU - Hossein Javadpour AU - Jim F. McCarthy AU - Lars Nolke AU - Karen C. Redmond AU - Jim J. Egan Y1 - 2020/07/01 UR - //www.qdcxjkg.com/content/56/1/1902413.abstract N2 - Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease that results in progressive respiratory failure and death. Antifibrotic therapy has been shown to slow disease progression [1, 2]. For many patients [3], lung transplantation is the only intervention recognised to provide significant survival benefit [4]. IPF commonly affects older patients, with a median age at diagnosis of 66 years old [5]. Without transplantation, the median survival from diagnosis is 2–4 years [5]. However, registry data indicates impaired outcomes following lung transplantation for older patients 6]. These data have prompted many centres in Europe to avoid offering transplantation to older IPF patients.This study demonstrates a clinically meaningful survival benefit of lung transplantation for IPF patients aged ≥65 years http://bit.ly/39pwH2h ER -